<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972422</url>
  </required_header>
  <id_info>
    <org_study_id>c3ZTCN100</org_study_id>
    <nct_id>NCT04972422</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of ZN-c3 in Chinese Subjects</brief_title>
  <official_title>A Phase 1b Study of ZN-c3 as a Single Agent in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zentera Therapeutics HK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zentera Therapeutics HK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability,&#xD;
      efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN c3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of Dose Escalation and Dose Expansion component in Chinese subjects with&#xD;
      solid tumors, described briefly as follows:&#xD;
&#xD;
      Dose Escalation: Single Agent Dose Escalation of ZN-c3 in solid tumors.&#xD;
&#xD;
      Dose Expansion: Single Agent ZN-c3 in solid tumors at the RP2D dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>Until 30 days after the last dose of study drug</time_frame>
    <description>Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of dose-limiting toxicities (DLTs) in DLT evaluable subjects during Cycle 1</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Single Agent Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZN-c3</intervention_name>
    <description>ZN-c3 is a study drug</description>
    <arm_group_label>Single Agent Dose Escalation</arm_group_label>
    <other_name>Study Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written informed consent prior to initiation of any study-related&#xD;
             procedures that are not considered standard of care.&#xD;
&#xD;
          2. Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of&#xD;
             informed consent.&#xD;
&#xD;
          3. Adequate hematologic and organ function as defined by the following criteria:&#xD;
&#xD;
               1. ANC ≥ 1.5 × 109/L; excluding measurements obtained within 7 days after daily&#xD;
                  administration of filgrastim/sargramostim or within 3 weeks after administration&#xD;
                  of pegfilgrastim.&#xD;
&#xD;
               2. Platelet count ≥ 100 × 109/L; excluding measurements obtained within 3 days after&#xD;
                  transfusion of platelets.&#xD;
&#xD;
               3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper&#xD;
                  limit of normal (ULN). If liver function abnormalities are due to underlying&#xD;
                  liver metastases, AST and ALT ≤ 5 x ULN.&#xD;
&#xD;
               4. Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.&#xD;
&#xD;
               5. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.&#xD;
&#xD;
          4. Female subjects of childbearing potential must have a negative serum beta human&#xD;
             chorionic gonadotropin test.&#xD;
&#xD;
          5. Male subjects and female subjects of childbearing potential must agree to use an&#xD;
             effective method of contraception per institutional standard prior to the first dose&#xD;
             and for 90 days after the last dose of ZN-c3.&#xD;
&#xD;
          6. Willingness and ability to comply with scheduled visits, treatment plan, laboratory&#xD;
             tests and other study procedures.&#xD;
&#xD;
          7. Willingness to practice adequate sun protection (use of sunscreen or sun-protective&#xD;
             clothing or limitation of sun exposure).&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤1&#xD;
&#xD;
          9. Subjects must have a solid tumor with advanced or metastatic disease, refractory to&#xD;
             standard therapy or for whom no standard therapy is available, or the subject is&#xD;
             ineligible for standard therapy(ies).&#xD;
&#xD;
         10. Measurable or evaluable disease per RECIST version 1.1.&#xD;
&#xD;
         11. Subjects with advanced or metastatic disease, refractory to standard therapy or for&#xD;
             whom no standard therapy is available, or the subject is ineligible for standard&#xD;
             therapy(ies).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following treatment interventions within the specified time frame prior to&#xD;
             Cycle 1 Day 1:&#xD;
&#xD;
               1. Major surgery within 28 days (the surgical incision should be fully healed prior&#xD;
                  to study drug administration).&#xD;
&#xD;
               2. Radiation therapy within 21 days; however, if the radiation portal covered ≤ 5%&#xD;
                  of the bone marrow reserve, the subject is eligible irrespective of the end date&#xD;
                  of radiotherapy.&#xD;
&#xD;
               3. Any prior systemic therapy regardless of the stop date, but the subject must have&#xD;
                  recovered to eligibility levels from prior toxicity.&#xD;
&#xD;
               4. Autologous or allogeneic stem cell transplant within 3 months.&#xD;
&#xD;
               5. Current use of an investigational agent that is not expected to be cleared by the&#xD;
                  first dosing of study drug or that has demonstrated to have prolonged side&#xD;
                  effects. Subjects should have recovered from the side effects to a Grade 0 or 1&#xD;
                  (except alopecia).&#xD;
&#xD;
          2. A serious illness or medical condition(s) including, but not limited to, the&#xD;
             following:&#xD;
&#xD;
               1. Brain metastases that require immediate treatment or are clinically or&#xD;
                  radiologically unstable (i.e., have been stable for &lt; 1 month). If receiving&#xD;
                  steroids, subjects must be receiving a stable to decreasing corticosteroid dose&#xD;
                  during at least 1 week before enrollment.&#xD;
&#xD;
               2. Leptomeningeal disease that requires or is anticipated to require immediate&#xD;
                  treatment.&#xD;
&#xD;
               3. Myocardial impairment of any cause (e.g. cardiomyopathy, ischemic heart disease,&#xD;
                  significant valvular dysfunction, hypertensive heart disease, and congestive&#xD;
                  heart failure) resulting in heart failure by New York Heart Association Criteria&#xD;
                  (Class III or IV).&#xD;
&#xD;
               4. Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
                  abnormality that may increase the risk associated with study participation or&#xD;
                  study drug administration, or may interfere with the interpretation of study&#xD;
                  results, and in the judgment of the Investigator would make the subject&#xD;
                  inappropriate for entry into this study.&#xD;
&#xD;
               5. Significant gastrointestinal abnormalities, including an inability to take oral&#xD;
                  medication, requirement for IV alimentation, active peptic ulcer, chronic&#xD;
                  diarrhea or vomiting considered to be clinically significant in the judgment of&#xD;
                  the Investigator, or prior surgical procedures affecting absorption.&#xD;
&#xD;
               6. Active or uncontrolled infection. Subjects with an infection receiving treatment&#xD;
                  (antibiotic, antifungal or antiviral treatment) may be entered into the study but&#xD;
                  must be afebrile and hemodynamically stable for ≥ 72 hours.&#xD;
&#xD;
          3. Unresolved toxicity of Grade &gt; 1 attributed to any prior therapies (excluding Grade 2&#xD;
             neuropathy, alopecia or skin pigmentation).&#xD;
&#xD;
          4. Prior therapy with ZN-c3 or known hypersensitivity to any drugs similar to ZN c3 in&#xD;
             class.&#xD;
&#xD;
          5. Prior therapy with a WEE1 inhibitor.&#xD;
&#xD;
          6. Pregnant or lactating females (including the cessation of lactation) or females of&#xD;
             childbearing potential who have a positive serum pregnancy test within 14 days prior&#xD;
             to Cycle 1 Day 1.&#xD;
&#xD;
          7. Subjects with active (uncontrolled, metastatic) second malignancies or requiring&#xD;
             therapy.&#xD;
&#xD;
          8. Individuals who are judged by the Investigator to be unsuitable as study subjects.&#xD;
&#xD;
          9. 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of&#xD;
             &gt; 450 msec, except for subjects with atrioventricular pacemakers or other conditions&#xD;
             (e.g., right bundle branch block) that render the QT measurement invalid.&#xD;
&#xD;
         10. History or current evidence of congenital long QT syndrome.&#xD;
&#xD;
         11. Administration of strong and moderate CYP3A4 inhibitors and inducers as well as strong&#xD;
             and moderate P-gp inhibitors.&#xD;
&#xD;
         12. Patients with active HBV and HCV infection: HBV DNA is higher than the upper limit of&#xD;
             reference value if anti-HBC positive, HCV virus copy number exceeds the lower limit of&#xD;
             detection method.&#xD;
&#xD;
         13. A known history of human immunodeficiency virus infection or serum anti-HIV positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xu Li, M.Sc</last_name>
    <phone>+86 15902153353</phone>
    <email>xli@zenteratx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianshu Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan University Huaxi Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongsheng Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Pan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

